In Case of a Shortage: Strategies to Conserve the Immune Globulin Supply
What can be done in the event of a severe shortage of IG products, whose production is entirely reliant on a continuous supply of IgG-rich plasma donated at more than 800 dedicated U.S. collection facilities?
The Promise of COVID-19 Hyperimmune Immune Globulin Therapy
As of this writing, NIAID and industry collaborators are also finalizing the design of a large-scale trial to assess whether COVID-Ig can reduce the rate of hospitalization and other medical encounters in earlier-stage COVID-19 patients exhibiting mild to moderate symptoms.
No Place Like Home: The Growing Acceptance of Subcutaneous Immune Globulin
Is SCIG well-accepted by most patients either previously treated with IVIG or just starting out on IG therapy?
FDA Approves Sandoz’s Ziextenzo as 24th Biosimilar
The U.S. Food and Drug Administration (FDA) has approved Ziextenzo (pegfilgrastim-bmez), the 24th biosimilar approval in the U.S.
A Guide to Immune Globulin Billing and Reimbursement
Reimbursement for expensive immune globulin (IG) therapies can be challenging and frustrating for providers. Here’s a guide to help ensure they are reimbursed for the cost of these medications.
Octapharma Introduces New SCIG Product and IgCares Program
Octapharma introduced its newest product, Cutaquig (immune globulin subcutaneous [human] 16.5% solution) at the Immune Deficiency Foundation (IDF) National Conference in June.
Anti-Influenza Hyperimmune Immune Globulin Not Effective in Hospitalized Adults with Influenza Infection
A trial was conducted to assess the safety and efficacy of hIVIG (in conjunction with standard care) in adults hospitalized with laboratory-confirmed influenza A or B infection.
ADMA Biologics Receives U.S. Patent for Treatment and Prevention of Pneumococcal Infections
The U.S. Patent and Trademark Office has issued a patent to ADMA Biologics for methods of treatment and prevention of S. pneumonia infection.
SCIG with Recombinant Human Hyaluronidase Is Safe and Preferred vs IVIG by Some Multifocal Motor Neuropathy Patients
A team of Dutch investigators enrolled 18 multifocal motor neuropathy (MMN) patients on intravenous immune globulin(IVIG) treatment in a prospective open-label study to evaluate the comparative safety of treatment with 10% human immune globulin whose subcutaneous administration is facilitated with recombinant human hyaluronidase (fSCIG) (HyQvia).
Patients on IVIG Therapy for Neurological Disorders Successfully Transitioned to SCIG Therapy
Canadian investigators at Ottawa Hospital have reported a very high success rate with a nurse-led individualized program to facilitate a smooth transition in patients with neurological disorders from chronic intravenous immune globulin (IVIG) to subcutaneous immune globulin (SCIG) treatment.
